Comparison of therapeutic effect of repaglinide and metformin combination with repaglinide and glibenclamide combination in treatment of type 2 diabetes

Objective To compare the difference in clinical effect and safety of metformin combined with repaglinide and metformin combined with glibenclamide in the treatment of type 2 diabetes,and guide the clinical medication. Methods Total 160 cases of type 2 diabetes were randomly divided into control group( Group A) and observation group( Group B) with 80 cases in each group. The group A received metformin and repaglinide,while group B received metformin and glibenclamide. The course was 6 months in both groups. The clinical guidelines,rate reaching the standard level,influence on renal function and liver function of patients,and the incidence of side effects. Results The main clinical guidelines were improved in both groups. The rate reached the normal range for blood sugar level 2 hours after eating was 95. 0% in the group A,and was higher than 85. 0% in the group B. The levels of TBIL,ALT,SCr and BUN showed no difference in each group and between groups. The incidence of adverse reaction was 6. 25% in group A,and obviously lower than 15. 0% in the group B. Conclusion The hypoglycemic effects repaglinide combined with metformin is more effective for the patients type 2 diabetes,with a lower incidence of adverse reaction and higher safety,can be the first choice in the clinical treatment of type 2 diabetes.